FDA-&-EMA-New-Drug Approvals(Mid-2020 Recap)-insert
X

Find Drugs for Infections and Infectious Diseases in Phase I Clinical Development

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual BoothGlobal Pharmaceutical Dosage Solutions Company

            Contact the Supplier

            Lead Product(s): mRNA-1273

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: Moderna Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration May 01, 2020

            Details:

            Moderna plans to establish manufacturing suites at Lonza’s facilities in the United States and Switzerland for the manufacture of mRNA-1273 at both sites.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): NVX-COV2373,Matrix-M

            Therapeutic Area: Infections and Infectious Diseases Product Name: NVX-COV2373

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: U.S. government

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration July 27, 2020

            Details:

            FUJIFILM Diosynth will support COVID-19 vaccine candidate manufacturing, as part of Operation Warp Speed, a U.S. government program that aims to begin delivering millions of doses of a safe, effective vaccine for COVID-19 to the U.S. population.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ARCoV

            Therapeutic Area: Infections and Infectious Diseases Product Name: ARCoV

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 24, 2020

            Details:

            ARCoV is a messenger RNA vaccine which uses technology similar to candidates being developed by Moderna and BioNtech and Pfizer.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): NVX-COV2373,Matrix-M

            Therapeutic Area: Infections and Infectious Diseases Product Name: NVX-COV2373

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: Fujifilm Diosynth Biotechnologies

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement July 23, 2020

            Details:

            The Agreement aims to manufacture bulk drug substance for NVX-CoV2373, Novavax’ COVID-19 vaccine candidate. FDB’s site in Morrisville, North Carolina has begun production of the first batch of NVX-CoV2373.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Aspartyl-alanyl-diketopiperazine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Ampion

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 20, 2020

            Details:

            This newly described syndrome in children resembles Kawasaki Disease and exhibits many signs, symptoms and pathology that could be treated by intravenous AmpionTM either alone or in combination with intravenous immunoglobulins.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Allocetra-OTS

            Therapeutic Area: Infections and Infectious Diseases Product Name: Allocetra

            Highest Development Status: Phase I Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 20, 2020

            Details:

            Preclinical data from the studies demonstrate the ability of AllocetraTM to broadly resolve cytokine storm-associated organ failure and reduce mortality by 90% in a murine cecal ligation and puncture (CLP) animal model of severe sepsis.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): NVX-COV2373,Matrix-M

            Therapeutic Area: Infections and Infectious Diseases Product Name: NVX-COV2373

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 20, 2020

            Details:

            NVX‑CoV2373 was created using Novavax’ recombinant nanoparticle technology to generate antigen derived from the coronavirus spike protein and contains its patented Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): SAB-185

            Therapeutic Area: Infections and Infectious Diseases Product Name: SAB-185

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Merck & Co. Inc.

            Deal Size: $14.0 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing July 17, 2020

            Details:

            Since March of 2020, SAB has announced $36.4 million in funding awarded for its rapid response program and the development of an anti-SARS-CoV-2 fully human polyclonal antibody therapeutic, SAB-185, poised to begin clinical trials this month.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): COVID-19 antiviral antibody

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 17, 2020

            Details:

            Celltrion’s COVID-19 antiviral antibody treatment candidate has been proven to be effective in neutralising different kinds of coronavirus related strains including the mutated G-variant strain of SARS-CoV-2 (D614G variant).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): V-306

            Therapeutic Area: Infections and Infectious Diseases Product Name: V-306

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: $8.0 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing July 16, 2020

            Details:

            The financing will ensure the company can complete the phase 1 clinical trial of its lead asset V-306 in RSV, advance pre-clinical development of its vaccine candidates against SARS-CoV-2, progress other research collaborations and strengthen the team.

            PharmaCompass